Pancreatic Cancer Research

Clinical trialPhase 3Completed

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Outcome
Results posted; single-arm, no comparison
Phase
Phase 3
Status
Completed
Study type
Interventional
Start
February 2009
Ended
December 2015
Enrollment
89 participants
Sites
25
Primary outcomes
Adverse Events
Sponsor type
Industry
Results posted
17 February 2017
Last update
12 October 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 12 October 2022
Primary outcome
Adverse EventsLanreotide Autogel: 40, n = 42Placebo: 46, n = 47Total: 86, n = 89Values: participants with any TEAEsTime frame: Throughout the study until the completion/early discontinuation visit.No analysis posted for this outcome (outcome 1)
Participants
Lanreotide Autogel: 101 started, 16 completedPlacebo: 103 started, 9 completed
Serious adverse events
Lanreotide Autogel: 11 of 42Placebo: 14 of 47Total: 25 of 89Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
PFS · Progression Free Survival (PFS): Kaplan-Meier Estimate
Lanreotide Autogel - Randomised Treatme… 154.14 (123.57 to 237.43), n=101; Placebo - Randomised Treatment in Study… 72.00 (48.43 to 84.57), n=103 [median weeks, 95% Confidence Interval]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study, 2-55-52030-726 (NCT00353496).

Detailed description public domain (ClinicalTrials.gov)

While somatostatin analogue treatment is the primary medical therapy for patients with hormone related symptoms and is indicated for the treatment of hormone related symptoms in many international countries, there is no reference standard medical therapy for asymptomatic patients. A 96-week study (Study 2-55-52030-726 (726), NCT00353496) was conducted to investigate the effect of lanreotide Autogel on progression free survival (PFS) in patients with well or moderately differentiated nonfunctioning enteropancreatic NET. While Study 726 was ongoing, the sponsor considered that therapy with lanreotide Autogel should continue to be an option to patients with stable disease at the end of the 96-week treatment period. This extension study was therefore initiated (Study 2-55-52030-729 (729)) which investigated the long term safety of treatment with lanreotide Autogel and enabled investigators to continue to treat their patients who had stable disease, as well as to treat placebo patients who experienced disease progression during the initial 96-week study (Study 726).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Adverse Events [Throughout the study until the completion/early discontinuation visit.]. Number, participants with any TEAEs. Lanreotide Autogel (n=42): 40; Placebo (n=47): 46; Total (n=89): 86.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression Free Survival (PFS): Kaplan-Meier Estimate [Throughout the study (every 24 weeks and at completion/withdrawal visit)]. Median, weeks (95% Confidence Interval). Lanreotide Autogel - Randomised Treatment in Study 726 (n=101): 154.14 (123.57 to 237.43); Placebo - Randomised Treatment in Study 726 (n=103): 72.00 (48.43 to 84.57).